(Q34172070)

31 July 2017

1 reference

title

Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21420850

27 November 2024

3

William Kelton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21420850

27 November 2024

author name string

Sang Taek Jung

1

1 reference

31 July 2017

Tae Hyun Kang

2

1 reference

31 July 2017

George Georgiou

4

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21420850

27 November 2024

publication date

21 March 2011

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S0958166911000413?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

https://api.elsevier.com/content/article/PII:S0958166911000413?httpAccept=text/plain

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Current Opinion in Biotechnology

27 November 2024

published in

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

858-867

1 reference

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 July 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1074/JBC.M202069200

Glycosylation as a strategy to improve antibody-based therapeutics

1

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Production of complex human glycoproteins in yeast

27 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

27 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

27 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system

27 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

27 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineering Antibodies for Therapy

27 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Synthesis and assembly of a full-length human monoclonal antibody in algal chloroplasts

27 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

27 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

27 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.

27 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus

27 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

27 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers

27 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

27 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Targeting the HGF/c-Met axis: state of play.

27 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Preparative expression of secreted proteins in bacteria: status report and future prospects

27 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions

27 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody

27 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies

27 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.

27 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain

27 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.

27 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Glycosylation as a strategy to improve antibody-based therapeutics

27 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

27 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses

27 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

27 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineering host cell lines to reduce terminal sialylation of secreted antibodies

27 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineered therapeutic antibodies with improved effector functions

27 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Production of therapeutic antibodies with controlled fucosylation

27 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Fcgamma receptors as regulators of immune responses

27 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies.

27 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity

27 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

27 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

27 November 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

27 November 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

27 November 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile

27 November 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

27 November 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells

27 November 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Structure of the murine unglycosylated IgG1 Fc fragment

27 November 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry

27 November 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic

27 November 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineered antibody Fc variants with enhanced effector function

27 November 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

27 November 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

27 November 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors

27 November 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

27 November 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

27 November 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program

27 November 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

27 November 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes

27 November 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

27 November 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Enhanced antibody half-life improves in vivo activity

27 November 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates

27 November 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

27 November 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli

27 November 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Optimized expression of full-length IgG1 antibody in a common E. coli strain

27 November 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli

27 November 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening

27 November 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies

27 November 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

"Inclonals": IgGs and IgG-enzyme fusion proteins produced in an E. coli expression-refolding system

27 November 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.COPBIO.2011.03.002

27 November 2024

Identifiers

1 reference

31 July 2017

1 reference